# US 2013/0157939 A1 · Compositions for gastric delivery of active agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157939 A1
- Document ID: US20130157939A1
- Status: Published application
- Kind: A1
- Application number: 13/817,931
- Filed: 2011-08-18
- Published: 2013-06-20
- Earliest claimed: 2010-08-23
- Inventors: Shmuel Ben-Sasson
- Web page: https://patentgrep.com/patent/US20130157939A1

## CPC

- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to compositions, including pharmaceutical compositions for oral administration, comprising: at least one therapeutically active agent; at least one surface active agent; at least one ester of poly-carboxylic acid and/or at least one ester of an aromatic carboxylic acid; and a non-aqueous medium, for use in the gastric absorption of said at least one therapeutically active agent of the composition and methods of oral administration of at least one therapeutically active agent utilizing compositions of the invention.

## Claims

### Claim 1

A composition comprising:
at least one therapeutically active agent;
at least one surface active agent;
at least one ester of poly-carboxylic acid; and
a non-aqueous medium.

### Claim 2

A composition comprising:
at least one therapeutically active agent;
at least one surface active agent;
at least one ester of poly-carboxylic acid; and
a non-aqueous medium;
for the gastric absorption of said at least one therapeutically active agent.

### Claim 3 (depends on 1)

A composition according to claim 1, wherein said at least one therapeutically active agent has poor to negligible gastrointestinal absorption.

### Claim 4 (depends on 1)

A composition according to claim 1, wherein said at least one therapeutically active agent is a macromolecule.

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8 (depends on 1)

A composition according to claim 1, wherein said at least one therapeutically active agent is selected from a hormone, growth factor, incretin, neurotrophic factor, anticoagulant, toxin, antibiotic, anti-fungal agent, antipathogenic agent, antigen, antibody, monoclonal antibody, antibody fragment, soluble receptor, immunomodulator, vitamin, antineoplastic agent, a cardiovascular agent, an antihypertensive agent, an agent used in the treatment of neurological disease, an agent capable of treating liver or kidney diseases, enzyme, gonadotropin, cytokine or any combination thereof

### Claim 9 (depends on 1)

A composition according to claim 1, wherein said at least one therapeutically active agent is selected from the group consisting of insulin, C-peptide, erythropoietin (EPO), glucagon-like peptide 1 (GLP-I), melanocyte stimulating hormone (ALPHA-MSH), parathyroid hormone (PTH), parathyroid hormone amino acids 1-34 (PTH(1-34)), growth hormone, peptide YY amino acids 3-36 (PYY(3-36)), calcitonin, interleukin-2 (IL-2), alphal-antitrypsin, granulocyte/monocyte colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), T20, monoclonal antibodies such as anti-TNF antibodies, interferon alpha, interferon beta, interferon gamma, luteinizing hormone (LH), follicle-stimulating hormone (FSH), enkephalin, dalargin, kyotorphin, basic fibroblast growth factor (bFGF), hirudin, hirulog, luteinizing hormone releasing hormone (LHRH), brain-derived natriuretic peptide (BNP), glatiramer acetate, coagulation factor VIII; coagulation factor IX, neurotrophic factors, human chorionic gonadotropin (hCG), tissue plasminogen activator (TPA), oxytocin, and any analogs thereof and combinations thereof.

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12 (depends on 1)

A composition according to claim 1, wherein said at least one therapeutically active agent comprises at least about 0.001 to about 20% wt of the total weight of said composition.

### Claim 13 (depends on 1)

A composition according to claim 1, wherein said at least one surface active agent is selected from a fatty acid or a salt thereof, bile acid or a salt thereof, abietic acid or a salt thereof or any combination thereof.

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17 (depends on 1)

A composition according to claim 1, wherein said non-aqueous medium comprises at least one mono-, oligo-, or poly-alcohol or any combination thereof.

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21 (depends on 1)

A composition according to claim 1, wherein said at least one ester of a poly-carboxylic acid is selected from C1-C8 alkyl ester and C6-C10 aromatic ester.

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30 (depends on 1)

A composition according to claim 1, further comprising at least one ester of an aromatic carboxylic acid.

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33 (depends on 1)

A composition according to any one of the preceding claims, claim 1, wherein said at least one ester of poly-carboxylic acid comprises at least about 5 to about 90% wt of total weight of said composition.

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36

(canceled)

### Claim 37

(canceled)

### Claim 38 (depends on 1)

A composition according to claim 1, for use in the oral administration of said at least one therapeutically active agent.

### Claim 39 (depends on 1)

A composition according to any claim 1, comprising: at least one therapeutically active agent; at least one of decanoic acid and lauric acid or any salt thereof; propylene-glycol and triethyl-citrate.

### Claim 40 (depends on 39)

A composition according to claim 39, further comprising ethyl-benzoate.

### Claim 41

(canceled)

### Claim 42

(canceled)

### Claim 43

(canceled)

### Claim 44

(canceled)

### Claim 45

(canceled)

### Claim 46

(canceled)
